Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
Date:1/28/2010

2008. Operating income increased 15 percent to $6.370 billion due primarily to higher gross margins. Excluding the impact of changes in foreign exchange rates, operating income would have increased approximately 14 percent. Other income (expense) improved $38.4 million to a net expense of $229.5 million. The effective tax rate for 2009 was 21 percent, up from 20.6 percent in 2008. Net income and earnings per share increased 16 percent, to $4.851 billion and $4.42, respectively. Excluding the impact of changes in foreign exchange rates, earnings per share would have increased approximately 14 percent.

Full-Year 2009 Significant Items Affecting Net Income

In addition to the fourth-quarter 2009 and 2008 significant items previously mentioned, net income for the full-year 2009 and 2008 was also affected by significant items occurring in the first nine months of 2009 and 2008. To reflect the impact of the ImClone acquisition as if the acquisition occurred on January 1, 2008, full-year 2008 pro forma earnings per share have been reduced by $.20 per share. For further detail, see the reconciliation below as well as the footnotes to the pro forma non-GAAP income statement later in this press release.

    
    
                                                      Full-Year     % Growth
                                                      ---------     --------
                                                    2009      2008
                                                    ----      ----
    
    Earnings (loss) per share (reported)           $3.94    $(1.89)    NM
    Charges related to Zyprexa litigation            .13      1.20
    Asset impairments and restructuring charges 
     (included in asset impairments, restr
'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... FARMINGDALE, N.Y. , Oct. 30, 2014  Misonix, ... surgical device company that designs, manufactures and markets innovative ... surgical specialties, announced today that it will report financial ... Thursday, November 6, 2014. The Company has scheduled a ... at 4:30 pm ET to review the results. ...
(Date:10/30/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... the United States , today announced ... Tel Aviv area of Israel.  ... platform of integrated R&D services to local customers. It ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
... Inc.,("CeloNova"), leading and accelerating healthcare solutions through ... breakthrough,results from the ATLANTA study of the ... the 20th Annual International Symposium on,Endovascular Therapy ... Corrado Tamburino, MD, President of the ...
... Ortho Women,s Health,& Urology(TM), Division of ... for ORTHO EVRA(R),(norelgestromin/ethinyl estradiol transdermal system) to ... includes two new additional estimates of relative,risk ... of 1.1,(indicating no increase in risk) and ...
Cached Medicine Technology:CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F 2ORTHO EVRA(R) Prescribing Information Updated 2ORTHO EVRA(R) Prescribing Information Updated 3
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
(Date:10/30/2014)... Nutrition Leaders, a popular online retailer ... and more, is currently hosting a sweepstakes on its ... is open to U.S. residents age 18 and over, ... One lucky winner will then be selected at random ... card to NutritionLeaders.com. , Nutrition Leaders’ managing director Kimba ...
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... Calif. (PRWEB) October 30, 2014 ... mutually exclusive concepts in the medical-grade skin care ... the development of uniquely potent topical dermatological products, ... System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant ... glycolic acid concentrations (50% and 70%) and a ...
(Date:10/30/2014)... PreDiabetes Centers , the pioneer ... shoppers with a supply of sugardown®, a chewable dietary ... blood sugar spikes. Learning how to control blood sugar ... of a diabetes prevention plan. , Shoppers who spend ... tube of sugardown. The offer expires November 30. ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Nutrition Leaders Announces Gift Card Sweepstakes 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2
... , , , NEW YORK, June 10 Vendome ... magazines and producers of the HEALTHCARE DESIGN.09 Conference announces the 2009 ... those who are unable to afford the cost of the conference ... fee. , , "We believe, as a company ...
... condition in which patients, aortic valves have just two leaflets instead ... up to two percent of the general population. The defect ... the valve and may results in a feeling of tightness in ... is easily diagnosed; often physicians can hear a "click" or a ...
... vomiting disease invades cells by attaching to particular sugar ... the conclusion of a thesis presented at the Sahlgrenska ... an important step in the development of a drug ... Winter vomiting disease is an infectious inflammation ...
... Illinois, USA June 10, 2009 The most important ... are the types of diagnostic tests performed and whether or ... they can ensure that only patients who need readily accessible ... study published today in the Journal of Hospital Medicine ...
... search platform to enable healthcare professionals to find Medicare ... 10 Vivisimo ( www.vivisimo.com ), a ... provider of education and information on healthcare regulatory compliance ... platform to power search on ...
... Organizations team pilot chronic care management tools in a ... Microsoft Corp., in collaboration with the University ... Family Medicine and Community Health, the city of Miami, ... in Miami,s Overtown neighborhood aimed at changing the way ...
Cached Medicine News:Health News:HEALTHCARE DESIGN.09 Announces Scholarship Program 2Health News:First-degree relatives of patients with bicuspid aortic valve should be screened 2Health News:Drugs against winter vomiting disease one step closer 2Health News:Availability of diagnostic tests drive success in hospitalist-run short-stay units 2Health News:HCPro Selects Vivisimo Velocity to Launch MedicareFind.com 2Health News:HCPro Selects Vivisimo Velocity to Launch MedicareFind.com 3Health News:The University of Miami Miller School of Medicine, the City of Miami, Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Using Collaborative Technology 2Health News:The University of Miami Miller School of Medicine, the City of Miami, Microsoft and Resolute Solutions Seek to Improve Care of Diabetic Populations Using Collaborative Technology 3
... IOL is a foldable silicone IOL. It ... and is designed to be inserted with ... Multifocal IOL is the first and only ... offer patients a full range of functional ...
1% Sodium Hyaluronate, 10mg/mL, sterile opthalmic injection...
... Ocucoat is a 2% Hydroxypropyl Methylcellulose solution ... surgeons performing high volume, small incision surgery. ... allows for rapid removal with minimal risk ... Ocucoat permits an unobstructed view of the ...
... Amvisc is the right viscoelastic agent for ... the planned extracap technique. Amvisc possesses sufficient ... removal. Amvisc is highly cohesive so that ... case is easily and quickly accomplished. Amvisc ...
Medicine Products: